View ValuationSCHOTT Pharma KGaA 향후 성장Future 기준 점검 2/6SCHOTT Pharma KGaA (는) 각각 연간 9.4% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.핵심 정보9.4%이익 성장률9.25%EPS 성장률Life Sciences 이익 성장20.2%매출 성장률6.1%향후 자기자본이익률14.17%애널리스트 커버리지Good마지막 업데이트22 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.공시 • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.New Risk • Jan 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.공시 • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.공시 • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share.New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공시 • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025공시 • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026공시 • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026공시 • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.공시 • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025이익 및 매출 성장 예측BIT:1SXP - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/20281,15817810926499/30/20271,08716184239119/30/20261,0131439022693/31/202699114359202N/A12/31/202599515011158N/A9/30/202598614635180N/A6/30/202597714749203N/A3/31/202597414866206N/A12/31/202495613546184N/A9/30/202495715079225N/A6/30/202494915022191N/A3/31/2024916135-3175N/A12/31/202390615836220N/A9/30/20238991526182N/A6/30/202387314372217N/A9/30/202282112529182N/A9/30/202164910134132N/A9/30/20205847719104N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1SXP 의 연간 예상 수익 증가율(9.4%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: 1SXP 의 연간 수익(9.4%)이 Italian 시장(11.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 1SXP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 1SXP 의 수익(연간 6.1%)이 Italian 시장(연간 5.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 1SXP 의 수익(연간 6.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1SXP의 자본 수익률은 3년 후 14.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 08:21종가2026/05/26 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SCHOTT Pharma AG & Co. KGaA는 23명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gaurav JainBarclaysPallav MittalBarclaysJonathon UnwinBarclays20명의 분석가 더 보기
Reported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
공시 • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
New Risk • Jan 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
공시 • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.
공시 • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share.
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공시 • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
공시 • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
공시 • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
공시 • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.
공시 • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025